![]()
Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | 1,2-dimethylhydrazine | decreases expression | ISO | RGD:1558145 | 6480464 | 1, 2-Dimethylhydrazine results in decreased expression of RAB33A mRNA | CTD | PMID:22206623 | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | EXP | | 6480464 | Tetrachlorodibenzodioxin affects the expression of RAB33A mRNA | CTD | PMID:22298810 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of RAB33A mRNA | CTD | PMID:32109520, PMID:33387578 | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | RGD:1558145 | 6480464 | Tetrachlorodibenzodioxin affects the expression of RAB33A mRNA | CTD | PMID:21570461, PMID:26377647 | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | RGD:1344985 | 6480464 | Tetrachlorodibenzodioxin results in increased expression of RAB33A mRNA | CTD | PMID:21632981 | 2,3,7,8-Tetrachlorodibenzofuran | decreases expression | EXP | | 6480464 | 2 more ... | CTD | PMID:32109520 | all-trans-retinoic acid | multiple interactions | ISO | RGD:1344985 | 6480464 | [Tretinoin co-treated with arsenic trioxide] results in increased expression of RAB33A mRNA | CTD | PMID:15894607 | all-trans-retinoic acid | decreases expression | ISO | RGD:1344985 | 6480464 | Tretinoin results in decreased expression of RAB33A mRNA | CTD | PMID:23724009 | arsenous acid | multiple interactions | ISO | RGD:1344985 | 6480464 | [Tretinoin co-treated with Arsenic Trioxide] results in increased expression of RAB33A mRNA | CTD | PMID:15894607 | arsenous acid | increases expression | ISO | RGD:1344985 | 6480464 | Arsenic Trioxide results in increased expression of RAB33A mRNA | CTD | PMID:20458559 | belinostat | multiple interactions | ISO | RGD:1344985 | 6480464 | [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB33A mRNA | CTD | PMID:27188386 | benzo[a]pyrene | multiple interactions | ISO | RGD:1558145 | 6480464 | Benzo(a)pyrene promotes the reaction [AHR protein binds to RAB33A promoter] | CTD | PMID:19654925 | benzo[a]pyrene | decreases methylation | ISO | RGD:1344985 | 6480464 | Benzo(a)pyrene results in decreased methylation of RAB33A promoter | CTD | PMID:27901495 | benzo[a]pyrene | decreases expression | ISO | RGD:1558145 | 6480464 | Benzo(a)pyrene results in decreased expression of RAB33A mRNA | CTD | PMID:22228805 | bisphenol A | increases expression | EXP | | 6480464 | bisphenol A results in increased expression of RAB33A mRNA | CTD | PMID:25181051 | bisphenol A | increases expression | ISO | RGD:1344985 | 6480464 | bisphenol A results in increased expression of RAB33A mRNA | CTD | PMID:27685785 | butanal | increases expression | ISO | RGD:1344985 | 6480464 | butyraldehyde results in increased expression of RAB33A mRNA | CTD | PMID:26079696 | chloroacetaldehyde | increases expression | ISO | RGD:1344985 | 6480464 | chloroacetaldehyde results in increased expression of RAB33A mRNA | CTD | PMID:25596134 | diarsenic trioxide | multiple interactions | ISO | RGD:1344985 | 6480464 | [Tretinoin co-treated with Arsenic Trioxide] results in increased expression of RAB33A mRNA | CTD | PMID:15894607 | diarsenic trioxide | increases expression | ISO | RGD:1344985 | 6480464 | Arsenic Trioxide results in increased expression of RAB33A mRNA | CTD | PMID:20458559 | dibutyl phthalate | decreases expression | EXP | | 6480464 | Dibutyl Phthalate results in decreased expression of RAB33A mRNA | CTD | PMID:21266533 | dimethylarsinic acid | multiple interactions | ISO | RGD:1558145 | 6480464 | [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of RAB33A mRNA | CTD | PMID:34876320 | dioxygen | increases expression | ISO | RGD:1344985 | 6480464 | Oxygen deficiency results in increased expression of RAB33A mRNA | CTD | PMID:25596134 | dorsomorphin | multiple interactions | ISO | RGD:1344985 | 6480464 | [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | endosulfan | increases expression | EXP | | 6480464 | Endosulfan results in increased expression of RAB33A mRNA | CTD | PMID:29391264 | entinostat | decreases expression | ISO | RGD:1344985 | 6480464 | entinostat results in decreased expression of RAB33A mRNA | CTD | PMID:26272509 | entinostat | multiple interactions | ISO | RGD:1344985 | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB33A mRNA | CTD | PMID:27188386 | ethanol | affects expression | ISO | RGD:1558145 | 6480464 | Ethanol affects the expression of RAB33A mRNA | CTD | PMID:30319688 | ethanol | increases expression | ISO | RGD:1558145 | 6480464 | Ethanol results in increased expression of RAB33A mRNA | CTD | PMID:30319688 | ethyl methanesulfonate | decreases expression | ISO | RGD:1344985 | 6480464 | Ethyl Methanesulfonate results in decreased expression of RAB33A mRNA | CTD | PMID:23649840 | ferroheme b | increases expression | ISO | RGD:1558145 | 6480464 | Heme metabolite results in increased expression of RAB33A mRNA | CTD | PMID:19191707 | formaldehyde | decreases expression | ISO | RGD:1344985 | 6480464 | Formaldehyde results in decreased expression of RAB33A mRNA | CTD | PMID:23649840 | heme b | increases expression | ISO | RGD:1558145 | 6480464 | Heme metabolite results in increased expression of RAB33A mRNA | CTD | PMID:19191707 | Licochalcone B | increases expression | ISO | RGD:1344985 | 6480464 | licochalcone B results in increased expression of RAB33A mRNA | CTD | PMID:33647349 | lipopolysaccharide | multiple interactions | ISO | RGD:1344985 | 6480464 | [S-(1, 2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of RAB33A mRNA | CTD | PMID:35811015 | mercury dibromide | decreases expression | ISO | RGD:1344985 | 6480464 | mercuric bromide results in decreased expression of RAB33A mRNA | CTD | PMID:26272509 | mercury dibromide | multiple interactions | ISO | RGD:1344985 | 6480464 | [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB33A mRNA | CTD | PMID:27188386 | metformin | increases expression | EXP | | 6480464 | Metformin results in increased expression of RAB33A mRNA | CTD | PMID:25596134 | methyl methanesulfonate | decreases expression | ISO | RGD:1344985 | 6480464 | Methyl Methanesulfonate results in decreased expression of RAB33A mRNA | CTD | PMID:23649840 | methylarsonic acid | multiple interactions | ISO | RGD:1558145 | 6480464 | [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of RAB33A mRNA | CTD | PMID:34876320 | N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal | decreases expression | ISO | RGD:1558145 | 6480464 | benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of RAB33A mRNA | CTD | PMID:25566086 | p-chloromercuribenzoic acid | decreases expression | ISO | RGD:1344985 | 6480464 | p-Chloromercuribenzoic Acid results in decreased expression of RAB33A mRNA | CTD | PMID:26272509 | p-chloromercuribenzoic acid | multiple interactions | ISO | RGD:1344985 | 6480464 | [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB33A mRNA | CTD | PMID:27188386 | panobinostat | multiple interactions | ISO | RGD:1344985 | 6480464 | [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB33A mRNA | CTD | PMID:27188386 | panobinostat | decreases expression | ISO | RGD:1344985 | 6480464 | panobinostat results in decreased expression of RAB33A mRNA | CTD | PMID:26272509 | paracetamol | decreases expression | EXP | | 6480464 | Acetaminophen results in decreased expression of RAB33A mRNA | CTD | PMID:33387578 | paraquat | increases expression | EXP | | 6480464 | Paraquat results in increased expression of RAB33A mRNA | CTD | PMID:32680482 | pentanal | increases expression | ISO | RGD:1344985 | 6480464 | pentanal results in increased expression of RAB33A mRNA | CTD | PMID:26079696 | phenobarbital | multiple interactions | ISO | RGD:1558145 | 6480464 | NR1I3 protein affects the reaction [Phenobarbital results in increased expression of RAB33A mRNA] | CTD | PMID:19482888 | phenobarbital | increases expression | ISO | RGD:1558145 | 6480464 | Phenobarbital results in increased expression of RAB33A mRNA | CTD | PMID:19482888 | phenylmercury acetate | decreases expression | ISO | RGD:1344985 | 6480464 | Phenylmercuric Acetate results in decreased expression of RAB33A mRNA | CTD | PMID:26272509 | phenylmercury acetate | multiple interactions | ISO | RGD:1344985 | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB33A mRNA | CTD | PMID:27188386 | protein kinase inhibitor | multiple interactions | ISO | RGD:1344985 | 6480464 | Protein Kinase Inhibitors inhibits the reaction [gardiquimod results in increased expression of RAB33A mRNA] | CTD | PMID:28003376 | S-(1,2-dichlorovinyl)-L-cysteine | multiple interactions | ISO | RGD:1344985 | 6480464 | [S-(1, 2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of RAB33A mRNA | CTD | PMID:35811015 | SB 431542 | multiple interactions | ISO | RGD:1344985 | 6480464 | [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | silicon dioxide | decreases expression | ISO | RGD:1344985 | 6480464 | Silicon Dioxide analog results in decreased expression of RAB33A mRNA | CTD | PMID:25895662 | sodium arsenate | multiple interactions | ISO | RGD:1558145 | 6480464 | [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of RAB33A mRNA | CTD | PMID:34876320 | sodium arsenite | multiple interactions | ISO | RGD:1558145 | 6480464 | [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of RAB33A mRNA | CTD | PMID:34876320 | sodium dodecyl sulfate | increases expression | ISO | RGD:1344985 | 6480464 | Sodium Dodecyl Sulfate results in increased expression of RAB33A mRNA | CTD | PMID:31734321 | sunitinib | increases expression | ISO | RGD:1344985 | 6480464 | Sunitinib results in increased expression of RAB33A mRNA | CTD | PMID:31533062 | temozolomide | decreases expression | ISO | RGD:1344985 | 6480464 | Temozolomide results in decreased expression of RAB33A mRNA | CTD | PMID:31758290 | titanium dioxide | decreases expression | ISO | RGD:1558145 | 6480464 | titanium dioxide results in decreased expression of RAB33A mRNA | CTD | PMID:29264374 | trichloroethene | decreases expression | EXP | | 6480464 | Trichloroethylene results in decreased expression of RAB33A mRNA | CTD | PMID:33387578 | trichostatin A | decreases expression | ISO | RGD:1344985 | 6480464 | trichostatin A results in decreased expression of RAB33A mRNA | CTD | PMID:24935251 | trichostatin A | increases expression | ISO | RGD:1344985 | 6480464 | trichostatin A results in increased expression of RAB33A mRNA | CTD | PMID:24935251 | triclosan | increases expression | ISO | RGD:1344985 | 6480464 | Triclosan results in increased expression of RAB33A mRNA | CTD | PMID:30510588 | triptonide | increases expression | ISO | RGD:1558145 | 6480464 | triptonide results in increased expression of RAB33A mRNA | CTD | PMID:33045310 | valproic acid | affects expression | ISO | RGD:1344985 | 6480464 | Valproic Acid affects the expression of RAB33A mRNA | CTD | PMID:25979313 | valproic acid | multiple interactions | ISO | RGD:1344985 | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB33A mRNA | CTD | PMID:27188386 | valproic acid | decreases expression | ISO | RGD:1344985 | 6480464 | Valproic Acid results in decreased expression of RAB33A mRNA | CTD | PMID:24935251, PMID:26272509 | valproic acid | increases expression | ISO | RGD:1344985 | 6480464 | Valproic Acid results in increased expression of RAB33A mRNA | CTD | PMID:24935251 | vinclozolin | increases expression | EXP | | 6480464 | vinclozolin results in increased expression of RAB33A mRNA | CTD | PMID:22570695 | |